News | May 02, 2026
Indoco Remedies to exit ophthalmic business in strategic sale to Sunways India
The transaction marks a clear portfolio reshuffle for Indoco
The transaction marks a clear portfolio reshuffle for Indoco
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
_256_384.png){kind=logo}
New plan integrates critical illness protection, market-linked health fund and preventive care platform for holistic financial and health security
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Subscribe To Our Newsletter & Stay Updated
